deficit

CaCCinh-A01 是钙激活氯离子通道和TMEM16A 抑制剂，IC50值分别为 10 和 2.1 μM。

Bavisant (JNJ-31001074) 是一种特异性和口服活性的人 H3 受体拮抗剂。 Bavisant 可用于作用机制的研究，包括觉醒和认知以及 ADHD 的治疗。

Oxidopamine hydrobromide (6-OHDA hydrobromide) 是一种神经递质多巴胺拮抗剂，可选择性地破坏多巴胺能神经元，是一种广泛使用的神经毒素。

Oxidopamine hydrochloride (6-Hydroxydopamine hydrochloride) 是一种神经递质多巴胺拮抗剂，可选择性地破坏多巴胺能神经元，是一种广泛使用的神经毒素。

Blonanserin (AD-5423) 是一种有效的5-HT2A 和多巴胺 D2 受体拮抗剂，Ki 为 0.812 和 0.142 nM，是一种非典型的抗精神病试剂。

Guanfacine hydrochloride (Intuniv) 是一种 α2A 肾上腺素受体激动剂，Kd=31 nM，具有抗高血压作用。

SB 202190 (FHPI) 是一种 p38 MAPK 抑制剂，可以抑制 p38α 和 p38β2 (IC50=50 100 nM)，具有选择性和细胞渗透性。SB 202190 具有抗肿瘤活性，还可以诱导人胚胎干细胞向心肌细胞分化。

Brexpiprazole HCl (OPC 34712 dihydrochloride) 是一种新型抗精神病药物。

Perospirone (Lullan) 是具有口服活性的5-HT2A 受体和多巴胺 D2受体的拮抗剂，也是5-HT1A 受体的部分激动剂，Ki 分别为 0.6 、1.4和2.9 nM。它是一种非典型的抗精神病剂，可用于精神分裂症的研究。

TAK-041 (NBI-1065846) 是一种选择性 GPR139激动剂，EC50为 22 nM，有用于精神分裂症阴性症状的研究潜力。

AR-08 是一种有效的 α2 肾上腺素能受体 (α2-adrenergic receptor) 激动剂，可用于研究多动症与注意力缺陷。

MK-0249 是一种具有口服活性、选择性和高效性的 histamine H3 受体拮抗剂（IC50：1.7 nM），可用于研究注意力缺陷和多动障碍。

MK-0249 FA 是一种具有口服活性、选择性和高效性的组胺 H3 反向激动剂，可用于研究成人注意力缺陷、多动症神经分裂和认知障碍。

Sofiniclin (ABT 894) is an agonist of nicotinic acetylcholine receptor (nAChR). It is used for the research for attention-deficit hyperactivity disorder (ADHD).

Cipralisant is a selective histamine H3 receptor antagonist in vivo, and an agonist in vitro (pKi: 9.9 for histamine H3 receptor; Ki: 0.47 nM for rat histamine H3 receptor). It has the potential for the treatment of attention-deficit hyperactivity disorde

FAPy-adenine HCl 是一种注意力缺陷多动综合征的代谢标记物，是 ROS 诱导 DNA 损伤的诱变产物。

GSK3-IN-9 (0713) 是一种选择性抑制糖原合成酶激酶3 (GSK3) 的化合物。GSK3-IN-9 在脆性X综合征、注意缺陷多动障碍 (ADHD)、儿童癫痫、智力残疾、糖尿病、急性髓性白血病 (AML)、自闭症以及精神障碍等疾病的研究中具有潜在应用。

TBTC is a selective agonist of retinoid X receptor α that acts by improving behavioral deficit in Alzheimer's disease model mice.

ABT-418, a nicotinic acetylcholine receptor (nAchR) agonist, is used potentially for the treatment of attention deficit disorder.

Manifaxine, a norepinephrine-dopamine reuptake inhibitor, is used potentially for the treatment of attention deficit.

S-8510 is a GABA-A receptor inverse agonist. S-8510 selectively potentiated pentylenetetrazol-induced convulsion without affecting minimal electroconvulsive shock- or strychnine-induced convulsion in ddY mice. S-8510 ameliorated memory impairment induced

Edivoxetine( LY2216684) is a selective norepinephrine reuptake inhibitor being developed as a treatment for attention deficit hyperactivity disorder (ADHD) and antidepressants.

Samelisant dihydrochloride (SUVN-G3031) is a antagonist of histamine H3 receptor with potential for the treatment of cognitive impairment, dementia, attention deficit hyperactivity disorder, epilepsy, sleep disorders, obesity, schizophrenia, eating disorders, and pain.

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3, with an IC50 of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD)[1][2]. SAR502250 (0.01-1 μM; 36 h) attenuates the Aβ25-35-induced cell death in rat embryonic hippocampal neurons[2]. SAR502250 (1-100 mg kg; a single p.o,) attenuates tau hyperphosphorylation in the cortex and spinal cord of transgenic mice expressing P301L tau[2].SAR502250 (10-30 mg kg; p.o. once daily for 7 weeks) improves the cognitive deficit in transgenic APP(SW) Tau(VLW) mice after infusion of Aβ25-35[2].SAR502250 (10-30 mg kg; a single p.o.) significantly increases the percentage of lever-presses in the inter-response time (IRT) bin (49-96 s), with a significant augmentation of the percentage of reinforced responses[2].SAR502250 (30 mg kg; i.p. once daily for 28 d) ameliorates chronic stress-induced degradation of the physical state of the mice coat[2].SAR502250 (10-60 mg kg; a single p.o.) decreases hyperactivity produced by psychostimulantsin mice[2]. [1]. Fukunaga K, et, al. 2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6933-7.[2]. Griebel G, et, al. The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents. Sci Rep. 2019 Dec 2;9(1):18045.